Gut Microbiome and Brain Chemistry Linked in Overlapping Reflux and Bowel Syndrome

For millions of people, the misery of a sensitive gut rarely travels alone. Patients with diarrhea-predominant irritable bowel syndrome, one of the most common functional gastrointestinal disorders worldwide, frequently report acid reflux symptoms as well, even when endoscopy shows no visible damage to the esophagus. This overlap, in which the bowel disorder coexists with nonerosive reflux disease, has long been treated as a clinical curiosity, managed with separate prescriptions and separate explanations. A new multi-omics study published in Gut Pathogens now argues that the two conditions may share a common molecular foundation, and that the key to understanding it lies in the intricate communication network known as the microbiota-gut-brain axis.

The research team, led by Yuedan Wang and Meiling She of the Institute of Digestive Diseases at Xiyuan Hospital of the China Academy of Chinese Medical Sciences, together with colleagues from several Chinese institutions, recruited twenty patients diagnosed with both diarrhea-predominant irritable bowel syndrome and nonerosive reflux disease, along with twenty matched healthy controls. Rather than examining a single biological layer, the investigators deployed three complementary technologies in parallel: untargeted liquid chromatography-mass spectrometry metabolomics on plasma, data-independent acquisition proteomics on the same blood samples, and 16S ribosomal RNA sequencing of fecal microbiota. The design allowed them to ask, for the first time in this patient group, whether the metabolic, protein-level, and microbial signatures of the comorbidity converge on shared pathways.

Before any molecule was measured, the team documented the human toll of the condition. Participants completed the short form-36 health survey and the hospital anxiety and depression scale, two validated instruments for quantifying quality of life and psychological distress. The results were striking in their selectivity. Patients showed largely preserved physical functioning, meaning they could carry out basic daily activities without major limitation. Yet their scores revealed severe deficits in role functioning, the capacity to fulfill work and social obligations, as well as in mental health and overall health perception. This pattern suggests that the burden of the combined disorders is felt less in mobility and more in mood, productivity, and subjective well-being, a profile consistent with the long-standing clinical observation that functional gut disorders and psychological distress travel together.

The molecular readout was enormous in scale. Plasma analysis identified 350 metabolites whose abundance differed significantly between patients and controls, while proteomics flagged 920 proteins present at divergent levels. These were not scattered changes. Pathway-level analysis revealed coordinated disruption across metabolic and immune-inflammatory systems, indicating that the comorbid state is accompanied by a systemic shift in how the body processes nutrients, signaling molecules, and inflammatory signals. The breadth of the perturbation underscores why single-biomarker studies of irritable bowel syndrome have struggled to produce a coherent picture: the disease state is not one broken circuit but a rewired network.

The fecal microbiome told a complementary story. Sequencing revealed enrichment of opportunistic pathogens alongside a depletion of beneficial commensal populations, the microbial allies that normally help ferment fiber, train the immune system, and maintain the gut barrier. This dysbiotic shift matters because gut microbes are not passive residents; they manufacture metabolites that enter the bloodstream, modulate immune tone, and communicate with the enteric and central nervous systems. A community tilted toward potential pathogens and away from protective species can therefore ripple outward, influencing physiology far beyond the colon wall.

When the researchers integrated all three data layers using Procrustes analysis, correlation networks, and random forest modeling, a central hub emerged: the microbiota-gut-brain axis. Among the shared pathways highlighted by the integrative analysis were forkhead box O signaling, a family of transcription factors governing oxidative stress responses and cellular survival; tryptophan metabolism, the biochemical route that feeds both serotonin synthesis and microbial indole production; and neuroactive ligand-receptor interactions, the molecular grammar of communication between nerves and their targets. That all three pathways sit at the intersection of microbial chemistry and neural signaling is precisely what one would expect if gut dysbiosis were helping to drive both intestinal symptoms and the reflux and mood disturbances that accompany them.

One of the most intriguing findings concerned a single bacterial genus. Klebsiella, an opportunistic pathogen enriched in the patients, showed a positive association with expression of monoamine oxidase A, the enzyme responsible for degrading monoamine neurotransmitters including serotonin, and a negative association with serotonin pathway metabolites. In other words, the more Klebsiella a patient carried, the more serotonin-degrading enzyme activity appeared and the fewer serotonin-related metabolites remained. Because serotonin is central to gut motility, visceral sensitivity, and mood regulation, a microbial influence on its availability offers a plausible mechanistic thread connecting diarrhea, reflux symptoms, and the anxiety and depression scores documented in the questionnaire data.

The study also ventured into the translational territory of diagnosis. Random forest modeling, a machine learning approach that evaluates which features best separate patient groups, identified a set of metabolites as potential diagnostic biomarkers for the comorbid condition. If validated in larger and more diverse cohorts, such a metabolic signature could eventually allow clinicians to distinguish patients whose overlapping symptoms share this molecular profile from those whose reflux and bowel complaints arise through different mechanisms, opening the door to more targeted therapies rather than the current trial-and-error approach.

The authors are careful about scope. With twenty patients and twenty controls, the study is a hypothesis-generating snapshot rather than a definitive population-level claim, and its cross-sectional design cannot establish whether microbial changes cause the disorders or result from them. The multi-omics integration, however, is what gives the work its force: convergent evidence from metabolites, proteins, and microbes pointing at the same axis is far harder to dismiss than any single measurement. The findings also carry practical implications for a condition often dismissed as purely psychological. If dysbiosis and disrupted neuroactive metabolism underlie the comorbidity, interventions aimed at restoring microbial balance, whether through diet, probiotics, or microbiota-targeted drugs, could plausibly address both gut and reflux symptoms simultaneously.

For now, the study stands as one of the most systematic molecular portraits yet of a patient group that has been clinically recognized but biologically neglected. It reframes diarrhea-predominant irritable bowel syndrome with concomitant nonerosive reflux disease not as two coincidental ailments but as a single integrated disturbance of the microbiota-gut-brain axis, one in which Klebsiella expansion, serotonin pathway disruption, forkhead box O signaling, and immune-inflammatory abnormalities form a coherent web. Confirming and extending that web will require longitudinal cohorts, intervention trials, and validation of the candidate biomarkers, but the direction of travel is clear. The gut, its microbes, and the brain are talking to each other, and in this debilitating comorbidity, the conversation appears to have gone badly wrong.

Subject of Research: Multi-omics analysis of diarrhea-predominant irritable bowel syndrome with concomitant nonerosive reflux disease

Article Title: Multi-omics analysis provides clues in understanding diarrhea-predominant irritable bowel syndrome with concomitant nonerosive reflux disease

Article References: Multi-omics analysis provides clues in understanding diarrhea-predominant irritable bowel syndrome with concomitant nonerosive reflux disease. (n.d.). https://doi.org/10.1186/s13099-026-00868-8

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00868-8

Keywords: irritable bowel syndrome, nonerosive reflux disease, microbiota-gut-brain axis, multi-omics, gut dysbiosis, metabolomics, proteomics, 16S rRNA sequencing, Klebsiella, serotonin metabolism, tryptophan metabolism, diagnostic biomarkers